

NEW CE CERTIFICATIONS FOR THREE NTC PRODUCTS BASED ON TIAB TECHNOLOGY

Milan, 22 July 2020 – NTC Srl, R&D focused pharmaceutical company headquartered in Italy, has obtained CE certifications for three medical devices based on TIAB technology: a new vaginal gel GENIGEL, a proctological cream-gel TIAHEM and a powder for wound care TIAHEL.

These are three new entries in the innovative NTC list of products “ready for partnering now”. This achievement is part of the NTC commitment in embracing new therapeutic approaches exploiting innovative formulations such as its patented TiAB & SiAB technologies.

TiAB and SiAB are made of micro-particles, based on titanium and silica dioxide respectively, designed to enhance the activity of silver ions (Ag+).

“NTC keeps developing new therapeutic solutions using the TiAB and SiAB technologies and keeps offering to its Partners globally new innovative medical devices” Riccardo Carbuicchio, Chairman and CEO of NTC, states. “During the last few years we have been working relentlessly, efficiently and swiftly, even during the lockdown due to COVID-19 emergency, and we managed to obtain EU certification in gynaecology for GENIGEL, in proctology for TIAHEM and in wound healing for TIAHEL. We are excited now to partner and to license-out these new products in Europe and in the rest of World”.

About NTC

NTC is a pharmaceutical company headquartered in Milan - Italy, with distributors and partners in more than 100 countries in the world, engaged in research, development, registration and commercialization of drugs, medical devices and food supplements in ophthalmology, and in other therapeutic areas including pediatrics, gynecology and gastro-metabolism. NTC offers to more than 200 partners innovative and high quality standard pharmaceutical products. For more information, please visit www.ntcpharma.com

For further information please contact:

NTC Srl
M. Claudia Nacci
Corporate Communication
Email: nacci.communication@ntcpharma.com
Tel: +393490592805